Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual disease (MRD) diagnostics, generally based on PCR analysis of rearranged antigen receptor genes. Although flow cytometry (FCM) can be used for MRD detection as well, discordant FCM and PCR results are obtained in 5-20% of samples. We evaluated whether 6-color FCM, including additional markers and new marker combinations, improved the results. Bone marrow samples were obtained from 363 ALL patients at day 15, 33 and 78 and MRD was analyzed using 6-color (218 patients) or 4-color (145 patients) FCM in parallel to routine PCR-based MRD diagnostics. Compared with 4-color FCM, 6-color FCM significantly improved the concordance with PCR-based MRD data (88% versus 96%); particularly the specificity of the MRD analysis improved. However, PCR remained more sensitive at levels o0.01%. MRD-based risk groups were similar between 6-color FCM and PCR in 68% of patients, most discrepancies being medium risk by PCR and standard risk by FCM. Alternative interpretation of the PCR data, aimed at prevention of false-positive MRD results, changed the risk group to standard risk in half (52%) of these discordant cases. In conclusion, 6-color FCM significantly improves MRD analysis in ALL but remains less sensitive than PCR-based MRD-diagnostics.
INTRODUCTION
Several studies have shown that monitoring of minimal residual disease (MRD) is a powerful prognostic factor in childhood acute lymphoblastic leukemia (ALL) at primary diagnosis and relapse as well as before and after stem cell transplantation (reviewed by Sczcepanski 1 ). So far, most MRD studies in childhood ALL have used PCR techniques using immunoglobulin (Ig) and/or T-cell receptor (TCR) gene rearrangements as patient-specific targets. This highly standardized method can be applied in B95% of patients with ALL and sensitivities of 10 À 4 can generally be obtained. [2] [3] [4] However, PCR-based risk group stratification is labor intensive, time consuming, highly complex and expensive. In contrast, flow cytometry (FCM)-based MRD analysis is much faster and relatively simple. In addition, FCM has the advantage of analysis at the single-cell level, allowing recognition and characterization of small subpopulations and exclusion of non-viable cells. Nevertheless, FCM has, so far, been hampered by a lower sensitivity (10 À 3 -10 À 4 ) and, to a lesser extent, a lower applicability (B90%) (reviewed by Ryan et al. 5 ). Several studies on direct comparison between FCM and molecular MRD data have been performed. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Generally, when 3/4-color FCM MRD data are qualitatively compared with PCRbased MRD data (using 0.01% as cutoff), the reported concordance varies from 70% to over 95%, depending on the time point and the related MRD level. A true quantitative comparison using both approaches was performed in only four studies (including at least 20 patients) and in samples in which both methods detected MRD levels above 0.01%, a significant relation was observed. 5,12,16,16b,17 Allowing a 10-fold difference between the two MRD results, a quantitative concordance between 75 and 90% was obtained in these studies. Altogether, these data show the potential of FCM MRD analysis, but also demonstrate that specificity and sensitivity of 3/4-color FCM are not yet as good as for the PCR-based MRD analysis.
The introduction of 3-color FCM in the early nineties and the introduction of 4-color FCM in the late nineties significantly improved the applicability and sensitivity for FCM MRD analysis. Whereas an aberrant immunophenotype could initially only be found in about 60% of childhood ALL cases using 3-color FCM, 18 the application of new marker combinations, introduction of new markers (for example, CD58 and CD99) and the introduction of 4-color FCM increased this frequency to over 90%. 9, 17, [19] [20] [21] [22] [23] It can be expected that the introduction of 6-color flow cytometers further improves the applicability and sensitivity of MRD detection in childhood acute leukemia. The use of 6-color flow cytometers not only increases the multicolor capabilities, but also allows addition of new informative markers as well as a more optimized composition of the antibody panels. We therefore evaluated our 4-color FCM MRD data obtained from 145 ALL patients analyzed during the first year of the Dutch DCOG-ALL10 protocol and our 6-color FCM MRD data obtained in 218 pediatric ALL patients subsequently enrolled into the DCOG-ALL10 protocol and compared the obtained MRD results with MRD data routinely obtained in parallel using real-time quantitative PCR (RQ-PCR) analysis of rearranged Ig/TCR genes.
MATERIALS AND METHODS

Patients and cell samples
Three hundred sixty-three children consecutively enrolled into the DCOG-ALL10 protocol were included in this study. The diagnosis of ALL was based on standard morphological, cytochemical, cytogenetic and immunological criteria (WHO 2008 classification). A diagnosis of B-cell precursor (BCP)-ALL was established in 317 patients, whereas 46 patients had a T-ALL. Bone marrow (BM) samples were obtained at primary diagnosis, at day 15 (during induction therapy), day 33 (during induction therapy) and day 78 (post induction therapy). Samples from patients diagnosed at Erasmus MC, Rotterdam, were directly transported to the Department of Immunology and processed for FCM and PCR-based MRD diagnostics as described below. Samples from other Dutch university medical centers were transported overnight to the DCOG where they were used for FCM and isolation of DNA. Isolated DNA was shipped to Sanquin, Amsterdam, or Erasmus MC, Rotterdam, for molecular MRD diagnostics. For all BM samples, mononuclear cells (MNC) were obtained from a single syringe using density gradient isolation (Ficoll-Isopaque, Pharmacia Amersham, Uppsala, Sweden). The obtained MNC were used for both molecular and FCM MRD analysis in order to achieve maximal comparability. The institutional review board of each participating center approved this study and informed consent for study participation was obtained from each patient or legal guardian.
PCR-based MRD analysis and stratification MRD levels were routinely determined by RQ-PCR analysis of rearranged Ig and/or TCR gene rearrangements. [24] [25] [26] [27] [28] [29] MRD diagnostics were performed in two central laboratories (Erasmus MC, Rotterdam and Sanquin, Amsterdam), both participating in the quality control rounds of the EuroMRD network (see www.euromrd.org). Diagnostic samples were screened for the presence of IGH, IGK-Kde, TCRG, TCRD, Vd2-Ja, and TCRB rearrangements using PCR heteroduplex analysis followed by sequencing of clonal rearrangements. 26 Southern blot analysis was performed for BCP-ALL patients using a BglII digest and hybridization with IGHJ6 or TCRDV2 probes. 30, 31 Oligoclonality was defined based on the number and intensities of the rearranged bands on the Southern blot in combination with the number of PCR detectable rearrangements within a certain locus. This information was used for subsequent selection of MRD-PCR targets. Patientspecific primers were designed and used in combination with germline probes and primers as described previously. 26 RQ-PCR data, performed in triplicate, were analyzed according to the EuroMRD guidelines (formerly European Study Group on MRD detection in ALL), using the guidelines to prevent false-negative MRD results, unless stated otherwise. 32 Briefly, a sample was considered MRD-positive if the C T value of at least one of the three replicates was X1.0 C T lower than the lowest C T of the background and within 4.0 C T from the highest C T value of the sensitivity. 32 Additionally, data were analyzed using alternative guidelines aiming at prevention of falsepositive MRD results. In this alternative analysis, a sample was considered MRD-positive if the C T value of at least two of the three replicates was X2.0 C T lower than the lowest C T of background and within 4.0 C T from the highest C T value of the quantitative range.
MRD-based risk group classification was according to the MRD-based risk groups as defined by the International Berlin-Freiburg-Mü nster Study Group (I-BFM-SG). 33, 34 Patients were considered high risk if the MRD level at both day 33 and day 78 was X5 Â 10 À 4 . Patients were considered standard risk if the BM samples at both day 33 and day 78 were MRDnegative (with at least one MRD-PCR target with a quantitative range p10 À 4 ). Remaining patients, in which high-risk and standard-risk classification could be excluded, were considered as medium risk.
Flow cytometric immunophenotyping
During the first year of the DCOG-ALL10 protocol (November 2004 till December 2005), 145 patients were analyzed using 4-color FCM, whereas 218 consecutive patients enrolled between January 2006 and April 2008 were analyzed by 6-color FCM. FCM was performed at two centers, the Dutch Childhood Oncology Group (DCOG, The Hague, The Netherlands) and the Department of Immunology, Erasmus MC (Rotterdam, The Netherlands). Laboratory protocols and antibody panels (clones, fluorochromes and suppliers) were fully standardized between both centers. For 4-color immunostainings (adapted from the BIOMED-1 program), 20, 21 the labelings CD34-FITC/CD19-PE/CD45-PerCP/CD22-APC and TdT-FITC/ CD19-PE/CD20-PerCP/CD10-APC were used in BCP-ALL patients, whereas in T-ALL the labelings TdT-FITC/CD7-PE/CD19-PerCP/CD3-APC, CD2-FITC/ CD7-PE/CD3-PerCP/CD5-APC and CD7-FITC/CD16.56-PE/SmCD3-PerCP/CyCD3-APC were used. For 6-color analysis, two standard labelings were used. In BCP ALL, the labelings CD58-FITC/CD19-PE/CD45-PerCP/CD10-APC/CD22-PECy7/ CD34-APCCy7 and TdT-FITC/CD19-PE/CD45-PerCP/CD10-APC/CD38-PECy7/ CD20-APCCy7 were used, whereas in T-ALL the labelings CD2-FITC/CD16.56-PE/CD45-PerCP/CD7-APC/CD5-PECy7/CD3-APCCy7 and CD99-FITC/CD16.56-PE/ CD45-PerCP/CD7-APC/CyCD3-PECy7/SmCD3-APCCy7 were applied. Thus, CD38 and CD58 were introduced as additional markers for BCP-ALL, 9,21,22 whereas for T-ALL TdT was replaced by CD99, 23 CD19 was removed and CD45 was introduced.
In order to reach high sensitivities, sufficient cells should be acquired. We aimed for 1 million cells per tube, resulting in a theoretical maximum sensitivity of 0.002%, taking into account that a minimum of 20 events is needed for a clear cluster of target cells. In some samples, particularly at day 15 or day 33, cell numbers were low and priority had to be given to molecular diagnostics. Consequently, o1 million cells were available for FCM of these samples. In 29% of day 15 samples and 11% of day 33 samples o200 000 cells could be acquired, limiting the theoretical sensitivity to X0.01%. In 29% of day 15 and 24% of day 33 samples between 200 000 and 500 000 could be acquired, limiting the theoretical sensitivity to 0.004-0.01%. At day 78 at least 500 000 cells could be acquired in over 91% of samples.
Analysis of FCM data files was performed in two centers (DCOG, The Hague and Erasmus MC, Rotterdam). During regular meetings the gating and analysis strategies were discussed and attuned. All MRD data are expressed as percentage MRD within the leukocytes. If the two tubes yielded different MRD results, the highest MRD level was taken.
To evaluate the inter-laboratory differences of data analysis and interpretation between both centers (DCOG and Erasmus MC), list mode data (fcs) files from 39 randomly selected samples of 16 patients (9 BCP-ALL and 7 T-ALL patients; including 12 samples at day 15, 13 samples at day 33 and 14 samples at day 78) were analyzed doubleblinded in both centers. Fully concordant quantitative results were obtained in all, except one single case (data not shown). In the single discordant case, MRD was scored negative by one center and very low positive (5 Â 
Statistical analysis
For continuous and categorical data the Mann-Whitney test or the w 2 -test/ Fisher's exact test was used in the comparison of groups. To test the equality of measurements from two different analytical methods (for example, 4-color FCM versus 6-color FCM, FCM versus PCR), Passing and Bablok regression was used. 35 In addition, Bland-Altman difference plots were applied to present the mean bias between two methods. Kappa statistics were applied to evaluate the agreement between two classifications (for example, MRD-based risk groups defined by FCM versus PCR). A P-value of 0.05 (two-sided) was considered the limit of significance in all analyses. Statistical analyses were performed using SPSS version 17.0 (IBM, Armonk, NY, USA) and MedCalc Version 11.6.1 (MedCalc Software, Mariakerke, Belgium).
RESULTS
MRD levels at different time points MRD levels were analyzed in a total of 339 follow-up samples by both 4-color FCM and PCR analysis and in a total of 559 follow-up samples by both 6-color FCM and PCR analysis. As expected, relatively high MRD levels were observed at day 15, whereas at day 33 and particularly at day 78 the majority of samples became MRD-negative using both methods (Figure 1 ).
4-color immunophenotyping: comparison with PCR-based MRD levels
A total of 339 follow-up samples, of which 223 were PCR-positive, were tested using 4-color FCM. Concordant qualitative results were obtained in 90.3% of samples using a cutoff of 0.1%; 87.8% of samples using a cutoff level of 0.01%; and 78.2% of Table 2) and T-ALL patients (Supplementary Table 3 ) were analyzed separately. As the level of concordance might be related to the number of cells that could be acquired with FCM, we evaluated whether the concordance between PCR and FCM was related to acquired cell numbers (o200 000, 200 000-500 000 and 4500 000 cells acquired). No significant differences were observed between these three categories for all three time points, although at day 78 the few samples with o500 000 cells acquired showed a slightly higher frequency of FCM À /PCR þ cases (Supplementary Figure 1) .
Of the 98 samples positive by PCR analysis and negative by FCM, six were positive o10 À 5 , 53 were positive o10
, 28 were positive o5 Â 10 À 4 and only 11 were quantifiable by PCR analysis. The mean value of the latter 11 samples was 2 Â 10 À 4 . Comparing specificities of 6-color versus 4-color FCM shows that the latter is less specific, both if a cutoff of 0.01% is chosen (8.7 versus 1.2% false-positive cases, Po0.0001) as well as without a cutoff (5.9 versus 0.2% false-positive cases, Po0.0001).
In 19% of discordant cases, samples were obtained from hyperdiploid patients; this percentage was comparable to the total percentage of hyperdiploid patients (24%), suggesting that additional copies of chromosome 14 (IGH), 2 (IGK) and/or 22 (IGL) did not influence the concordance between FCM and PCR. Figure 2b ). There were no significant differences between BCP-ALL and T-ALL (Supplementary Figure 2) . Also comparison of hyperdiploid versus non-hyperdiploid patients did not show significant differences (data not shown).
Evaluation of the concordance between the two MRD tubes used showed excellent correlations for both BCP-ALL (Supplementary Figure 3) and T-ALL (Supplementary Figure 4) . In only one sample MRD was detected in one 6-color tube only (MRD level: 3%). Furthermore, the concordance between FCM and PCR was highly comparable also when FCM data from tube 1 or tube 2 were analyzed separately (data not shown).
MRD-based risk groups. We subsequently used the PCR and 6-color FCM data to classify the patients as standard risk (MRD-negative at day 33 and day 78), high risk (MRD at day 33 and day 78 X5 Â 10 À 4 ), or medium risk (all others). In 171 patients, FCM MRD analysis could be performed at both time points. A comparison between the risk groups obtained by the two methods is shown in Table 2 . In 68% of patients, FCM and PCR MRD analysis resulted in similar risk group classification. In three patients classified as high risk by molecular MRD analysis, FCM resulted in medium-risk classification. Conversely, in two patients classified as high risk by FCM MRD analysis, PCR analysis resulted in medium-risk classification. In all these five cases, MRD levels at day 78 were just around the cutoff level of 5 Â 10 À 4 . One patient was negative at day 33 and day 78 by PCR analysis, while 0.01% Detailed analysis of discrepant cases. In virtually all 44 discrepant cases (PCR-based medium risk and FCM-based low risk), the number of cells acquired for FCM were 4500 000 at day 33 and day 78. In only one patient, the number of cells acquired at day 33 was o500 000 and FCM was negative, whereas PCR detected MRD (positive, o10 À 4 ).
Detailed analysis of the PCR data of the 44 discrepant patients showed that in 17 patients (39%) only one well from one target was considered positive, the other target being fully negative (Supplementary Table 6 ). The level of positivity of the single well generally was in the 10
À 5 range with a C T value outside the quantitative range. In an additional eight patients (18%), only two wells (either from the same Ig/TCR target or from two different targets) were positive, also in the 10
-10 À 5 range. Four patients (9%) had all three wells of one target positive, whereas the three wells of the other target (in three out of four patients slightly less sensitive) were fully negative. Finally, in the remaining 15 patients (34%) both Ig/TCR targets showed positive results in multiple wells.
Alternative MRD-based risk groups. If alternative guidelines for RQ-PCR data interpretation, aimed at prevention of false-positive MRD results, were applied, the concordance between the FCM-based and PCR-based risk groups increased to 85%. In particular, of the 44 patients initially interpreted as medium risk by PCR methods but standard risk by FCM, 23 (52%) were classified as standardrisk by PCR methods when the alternative guidelines were applied (Supplementary Table 6 ). Of these 44 patients, all treated according to the medium-risk arm of the DCOG-ALL 10 protocol, two patients suffered from a relapse. One patient, classified as standard risk using the alternative guidelines, had an isolated extramedullary relapse. The other patient, medium risk by both sets of guidelines, had a BM relapse one year after stop of therapy. Overall, in the FCM-based risk groups two out of eight HR patients (25%), nine out of 63 MR patients (14%), and five out of 99 LR patients (4%) relapsed. If alternative PCR criteria were used, eight out of 41 MR patients (20%) and five out of 120 LR patients (4%) relapsed.
Impact of oligoclonality. There was no significant difference in the level of concordance between 6-color FCM and PCR-based MRD data when monoclonal and oligoclonal patients were analyzed separately (overall level of concordance when no cutoff level is applied: 83% (monoclonal patients) versus 84% (oligoclonal patients); P ¼ 0.941 by Pearson w 2 ). If quantitative data were obtained both by 6-color FCM and PCR, the difference between both measurements was not significantly different between monoclonal and oligoclonal patients (median: 0.76 versus 0.70; P ¼ 0.969 by Mann-Whitney test).
DISCUSSION
The use of FCM MRD analysis is expected to be faster, cheaper and simpler than the currently widely used molecular MRD analysis (based on RQ-PCR analysis of rearranged Ig/TCR genes). Although Abbreviations: FCM, flow cytometry; HR, high risk; Ig, immunoglobulin; MR, medium risk; MRD, minimal residual disease; NA, not applicable; SR, standard risk; TCR, T-cell receptor. HR, MRD X5 Â 10 À 4 at both time points; SR, MRD-negative at both time points; MR all others. Six patients could not be classified using the molecular MRD analysis due to MRDnegativity but no Ig/TCR marker with at least a quantitative range of 10
Flow cytometric MRD analysis in childhood ALL B Denys et al the FCM MRD studies performed so far, using 3-or 4-color analysis, generally show comparable data, most studies also show that FCM MRD analysis is hampered by a lower sensitivity (10 À 3 -10
).
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Our current data, using 6-color FCM MRD analysis with inclusion of additional markers and new marker combinations, show that most MRD data are similar to PCR-based MRD analysis. As compared with 4-color FCM, 6-color FCM improved the concordance between FCM and PCR-based MRD analysis to over 95% (using a cutoff level of 0.01%). Importantly, 6-color FCM significantly improved the specificity as demonstrated by the virtual absence of PCR-negative/FCM-positive cases. Furthermore, risk-group classification based on two successive MRD time points (day 33 and day 78) was similar in 71% of patients, the majority of discordant cases being low risk by FCM and medium risk by PCR. FCM MRD detection is based on the detection of ALL cells with an aberrant immunophenotype within a large number of normal BCP cells. The possibility to use six different markers for such discrimination instead of four markers theoretically should improve the specificity of the FCM MRD analysis. Especially during massive BCP regeneration (for example, after induction therapy), 36, 37 such improved discrimination is helpful. In addition, improved characterization of the normal and leukemic cells will also facilitate the recognition of ALL cells despite the occurrence of immunophenotypic shifts, which frequently are apparent during the early phases of therapy. [38] [39] [40] [41] [42] Indeed, our current data show that 6-color FCM resulted in a higher concordance with molecular MRD data than 4-color FCM. Whereas using 4-color FCM 6% of samples were found to be positive by FCM only, this percentage dropped to almost 0% (0.2%) using 6-color FCM. Thus, the use of 6-color FCM (including new markers and new marker combinations) clearly improves the specificity of the immunophenotypic analysis. The observations that the intercept in the regression analysis showed a small but significant deviation from zero (that is, 0.15) and that the Bland-Altman plot demonstrates a mean difference of 1.6, which is confirmed by the recent study by Gaipa et al. 17 and indicate that the PCR-based MRD values generally are slightly higher than the FCM-based MRD data. Whether this is partly due to the fact that the PCR-based methods cannot discriminate between DNA from living and dead cells or that DNA from ALL cell may be present inside BM macrophages remains to be established.
Next to specificity, reliable MRD assays should also be sufficiently sensitive. At present, most ALL treatment protocols aim at a sensitivity of at least 10 À 4 . 3 Using a cutoff level of 10
(0.01%), the concordance between 6-color FCM and molecular MRD analysis was 495%, but this dropped down to 82% when no cutoff level was applied. A comparable decrease was recently shown in the AIEOP BFM ALL 2000 trial (concordance without cutoff: 71%; concordance with 0.01% cutoff: 80%). 17 In our study, most of the cases, in which molecular MRD analysis still yielded positive results but FCM could not detect MRD, were 'positive, not quantifiable' by PCR analysis. Two main issues may explain these data. First, as molecular MRD analysis had priority, in some cases insufficient cells (o1 000 000) could be acquired by FCM to reach the desired sensitivity. Analysis of the level of concordance between PCR and FCM of samples with low (o200 000), intermediate (200 000-500 000) or high numbers (4500 000) of acquired events however did not show significant differences. At day 15 and day 33, MRD levels frequently were sufficiently high to be detected despite the lower number of cells acquired in part of the samples. In the few samples with o500 000 cells acquired at day 78 a somewhat higher frequency of PCR þ /FCM À cases was observed (36% versus 20%), which might suggest that in these cases the low cell number may have hampered the FCM sensitivity. It is to be expected that acquisition of larger numbers of cells would increase the number of MRD-positive samples by FCM. 17 In this respect, one should realize that for reaching a certain sensitivity FCM MRD always needs B20-fold more cells than PCR-based MRD analysis, as a cluster of cells is required in FCM, whereas a single cell can already result in a positive PCR result. Second, for the molecular MRD analysis data are interpreted in such a way that false-negative results are prevented. That is, every amplification at least one PCR cycle apart from the amplification observed in normal buffy coat DNA is considered to reflect MRD. 32 As previously demonstrated, such interpretation may lead to false-positive MRD results in a significant number of cases (B10% of MRD-negative samples), particularly at time points at which the BCP compartment is massively regenerating. 43 Therefore, it may well be that a part of discrepant cases is not false-negative by FCM but rather scored false-positive by PCR analysis.
The concordance between 6-color FCM and molecular MRD analysis of 82% (if no cutoff is applied) is even slightly better than the inter-assay variation observed for molecular MRD analysis (74%). 44 By repeating the molecular MRD analysis, in about 10-15% of samples MRD results change form negative to positive or vice versa. Therefore, it is unavoidable that differences between molecular and FCM MRD analysis will exist when MRD levels are around the detection limits of the assays (or outside the quantitative range of the PCR assay). For MRD data above 0.01% (10 À 4 ; generally the quantitative range of the PCR assay) both methods however provide highly comparable quantitative results. Whether the low and non-reproducible MRD levels (o10 À 4 ) have a clinical meaning cannot be determined in the current study, in which molecular MRD diagnostics were used to stratify patients. However, other studies have shown that such low MRD levels have prognostic significance and that their detection is crucial for identification of truly low-risk patients. 33, 34, [45] [46] [47] One might expect that part of the discrepancies between PCRbased and FCM-based MRD data is related to oligoclonality, which may result in the monitoring of a subset of the ALL cells only. 48, 49 In our study, we defined oligoclonality based on both Southern blot results (both IGH and TCRD locus) and PCR results. We did however not find any significant differences in the concordance between FCM and PCR (either qualitative or quantitative) between monoclonal and oligoclonal patients. This may be explained by the fact that the PCR-based MRD analysis is always based on analysis of at least two patient-specific rearrangements and that always the highest MRD level is used as final MRD result.
Based on MRD results obtained at day 33 and day 78, patients included in the DCOG-ALL10 protocol are stratified as standard risk (MRD-negative at both time points), high risk (MRDX5 Â 10 À 4 at day 78), or medium risk (all others). When we used the same criteria for FCM-based risk group classification, concordant results were obtained in 68% of patients. Although this percentage seems low, it should be noted that it is comparable to the inter-assay variation seen in PCR-based classification (73%). 44 Unfortunately, MRD-based risk group data are not provided by the other large comparative FCM-PCR studies. 5,12,16,16b,17 Comparable to the differences between FCM and PCR, most differences in the interassay PCR comparison concerned standard risk versus medium risk. As indicated above, this is due to the conversion of MRDpositive to MRD-negative results (or vice versa) upon repeating the molecular MRD analysis in about 10-15% of samples. Furthermore, it should be noted that within the DCOG-ALL10 protocol the MRD-based standard-risk patients (as determined using RQ-PCR analysis) receive significant treatment reduction and that it is therefore crucial to prevent false-negative MRD data. Consequently, the RQ-PCR data are interpreted in such a way that false-negative MRD results are avoided, but this implies that low amplification levels that potentially do not reflect ALL cells but regenerating B-cells are considered as MRD positivity. 32, 43, 50 If alternative guidelines for data interpretation, used to prevent false-positive MRD results, were used, the concordance between FCM and PCR increased significantly (from 68 to 85%).
Flow cytometric MRD analysis in childhood ALL B Denys et al Which improvements are still necessary? Our current data show that the use of 6-color FCM MRD with introduction of additional markers and new marker combinations gives comparable results as PCR analysis in samples with MRD levels X0.01%. However, at low MRD levels (o0.01%) PCR analysis still appears to be superior. Importantly, low MRD levels (o0.01%) have prognostic significance and their detection is essential for identification of truly low-risk patients, particularly in treatment protocols that aim at treatment reduction for MRD-based low-risk patients. 34, 46 Future improvements should focus on a better and more objective discrimination of ALL cells from normal BCPs, for example, by the use of automated pattern recognition tools such as available in the new Infinicyt software 51, 52 and by the introduction of new markers. 53 Furthermore, introduction of X8-color-immunostainings allows combinations of multiple markers in a single tube (instead of multiple tubes), thereby facilitating the acquisition of large numbers of cells, which is essential to increase the sensitivity of FCM MRD. To reach FCM sensitivities of at least 10 À 5 (comparable to PCR), acquisition of at least 2 million cells is required. These are the aims of the currently ongoing EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). 54, 55 Finally, it remains to be established how many events should be required to consider a sample as positive and how many events should be required to actually quantify the percentage of MRD. Like for PCR-based MRD diagnostics, 32 introduction of definitions for quantitative range and sensitivity may further contribute to a uniform and standardized interpretation of FCM MRD data, which is a prerequisite for usage of FCM-MRD data in clinical treatment protocols. Of note, innovations in MRD technologies/approaches and related guidelines will most likely require adaptations in risk-group definitions. These have to be established before the new MRD approaches can be applied to reduce or increase therapy in clinical treatment protocols.
